Adult patients with plaque psoriasis have gained a new treatment option in the UK following the launch of LEO Pharma's Enstilar, the first fixed-combination, cutaneous foam spray for topical administration.
Psoriasis is a chronic, inflammatory skin disease, which is frequently accompanied by multiple physical and/or psychological comorbidities, such as psoriatic arthritis, diabetes, cardiovascular disease and depression, and is thought to affect up to three percent of the UK's population.
Enstilar (calcipotriol/betamethasone dipropionate) is a topical, alcohol-free, foam spray targeting all severities of plaque psoriasis, designed to provide patients with a convenient treatment option that can be easily applied.
LEO says clinical data shows that Enstilar is a more effective topical combination treatment than those currently available, with more than half of patients in clinical trials experiencing significant visible signs of improvement within four weeks and with some patients seeing improvements at one week.
This treatment can also improve quality of life (QoL), it says, quoting trial findings that 81% percent of psoriasis patients using Enstilar improvements after four weeks, with more than 70 percent reporting a reduction in itch-related sleep loss.
"We are delighted that there is a new, effective treatment choice now available to treat plaque psoriasis, an area of significant unmet need" noted John Warne, founder of the Psoriasis Help Organisation.
"Over 1.5 million people across the UK are living each day with the significant challenges of this chronic skin condition so we welcome new options to help them take back control."